These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pricing increases for cancer drugs sparks investigation. Venkatesan P Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213 [No Abstract] [Full Text] [Related]
23. White paper. The five myths of generic competition. A Pharma Matters report. March 2009. Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560 [TBL] [Abstract][Full Text] [Related]
24. Effect of generic drug competition on the price of prescription drugs in Ontario. Lexchin J CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888 [TBL] [Abstract][Full Text] [Related]
25. Indian generics companies go on spending spree. Jayaraman KS Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583 [No Abstract] [Full Text] [Related]
26. Generics battle brand names over mortality of drug patents. Betz R J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008 [No Abstract] [Full Text] [Related]
27. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
28. India's pharmaceutical industry: hype or high tech take-off? Malhotra P; Lofgren H Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398 [TBL] [Abstract][Full Text] [Related]
29. Strategic options for brand-name prescription drugs when patents expire. Mehta SC; Mehta SS Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309 [TBL] [Abstract][Full Text] [Related]
30. European Court of Justice. Baeyens A Eur J Health Law; 2020 May; 27(2):180-186. PubMed ID: 33652402 [No Abstract] [Full Text] [Related]
31. A shift on "pay for delay"--reopening doors for pharmaceutical competition? Hemphill Kraus EJ N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478 [No Abstract] [Full Text] [Related]
32. Long way down--pharmaceutical companies fear falling off 'patent cliff'. Sklan A Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667 [No Abstract] [Full Text] [Related]
33. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors]. Mahlich JC; Stadler I Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203 [TBL] [Abstract][Full Text] [Related]
34. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
35. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
37. The impact of generic substitution on price competition in Finland. Aalto-Setälä V Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226 [TBL] [Abstract][Full Text] [Related]
38. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond. Kelly C Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856 [TBL] [Abstract][Full Text] [Related]
39. Who Needs XR, LA, SR, XL, ER, or CR? Curtiss FR J Manag Care Pharm; 2005; 11(9):772-3, 775-6. PubMed ID: 16300421 [No Abstract] [Full Text] [Related]